
REVOLUTIONIZING CANCER IMAGING THROUGH QUANTUM TECHNOLOGIES.

UPCOMING EVENTS
October 24th 2024
In Person Annual Meeting @ TUM
​
​
PAST EVENTS
April 26, 2024
QuE-MRT General Assembly (Virtual)
​
5th October 2023
In Person Annual Meeting @ University of Freiburg, University Medical Centre, Dept. of Radiology, Medical Physics
​
May 2nd, 2023
QuE-MRT General Assembly (Virtual)
October 12th - 13th, 2022
QuE-MRT KICK-OFF Meeting @NVision, Ulm
​
September 1st, 2022
Project start
PARTNERS




















Funded by:
PUBLIC INFORMATION

MOTIVATION
Cancer is the second leading cause of mortality and morbidity worldwide. Despite new diagnostic tools, cancer remains a major societal challenge due to three factors: late diagnosis, invasive and costly diagnostic methods, and the difficulty and large amount of time required to assess the effectiveness of treatment. A breakthrough technology, "hyperpolarized magnetic resonance imaging", offers the first viable, non-radioactive solution for the non-invasive diagnosis and staging of cancer using a standard magnetic resonance imaging (MRI) scanner.

AIMS & APPROACH
The aim is to provide a clinically and commercially viable end-to-end platform to produce, detect and visualize quantum-enhanced hyperpolarized MRI agents in MRI scanners for animals and for humans. To achieve these goals, QuE-MRT brings together leading industrial, clinical and academic partners in the fields of quantum sensing and medical imaging, with combined expertise in translating quantum applications, bringing them to production readiness and clinical development.

INNOVATION & PROSPECTS
By exploiting a pure quantum state of hydrogen via coherent quantum control over a system of 5 to 7 spins, it has been demonstrated for the first time that quantum technologies can achieve clinically relevant polarization, at room temperature and in a short time, in a cost-effective and user-friendly manner. The consortium plans to validate and demonstrate the immense diagnostic value of the technology for oncology patients through initial clinical trials in high prevalence tumors.
